Galderma Group AG
1GALD
Company Profile
Business description
Galderma was formed in 1981 as a joint venture between Nestle and L’Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma’s science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
Contact
Zahlerweg 10
Zug6300
CHET: +41 584558592
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
7,600
Stocks News & Analysis
stocks
Avoid this overvalued ASX lithium producer
Why the market may be overpricing future earnings for this lithium producer.
stocks
Morningstar's verdict on SpaceX
Mark and Shani run through the business and what our analysts think about the IPO.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,994.70 | 7.20 | -0.08% |
| CAC 40 | 8,340.71 | 59.40 | -0.71% |
| DAX 40 | 24,893.58 | 246.11 | -0.98% |
| Dow JONES (US) | 51,666.84 | 45.87 | -0.09% |
| FTSE 100 | 10,428.85 | 9.00 | -0.09% |
| HKSE | 23,344.67 | 8.39 | 0.04% |
| NASDAQ | 25,587.04 | 579.56 | -2.21% |
| Nikkei 225 | 68,980.21 | 808.17 | -1.16% |
| NZX 50 Index | 13,382.87 | 52.90 | -0.39% |
| S&P 500 | 7,365.46 | 107.33 | -1.44% |
| S&P/ASX 200 | 8,793.00 | 8.40 | -0.10% |
| SSE Composite Index | 4,096.14 | 10.11 | -0.25% |